AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
TUESDAY, Nov. 13, 2018 -- Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events (MACE) among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease, according to a study...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | Heart | Pharmaceuticals | Study